Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.

Eli Glezer

Drew Spaventa

Singular Genomics Systems, Inc.

Spekle Solutions specializes in shaping market access and commercial strategies for life sciences. The company uses advanced analytical techniques and technology to provide customized solutions and insights.

Spekle Solutions

Watchmaker Genomics develops high-performance next-generation sequencing products for various applications including inherited disease and somatic oncology, rare variant detection, ctDNA analysis, transcriptomics, epigenetics, and single-cell assays.

Watchmaker Genomics

CMB Genomics provides clinical diagnostic testing, next generation sequencing, and laboratory genetic testing services. It focuses on enhancing access to molecular diagnostics in Africa through genetic testing and training.

Metric
Company Name	Singular Genomics Systems, Inc.	Spekle Solutions	Watchmaker Genomics	CENTRE FOR MOLECULAR BIOSCIENCES AND GENOMICS LIMITED
Symbol	OMIC
MSH ID	COM:SINGULARGENOMICS	COM:SPEKLESOLUTIONS	COM:WATCHMAKERGENOMICS	ORG:CMBGENOMICS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Instruments & Supplies	Consulting	Biotechnology	Biotechnology
Country	US	US	US	KE
Stage			Series A
Employee Count	255
Website	singulargenomics.com	speklesolutions.com	watchmakergenomics.com	cmbgenomics.org
LinkedIn
Founders

Metric
Market Cap	19.05M
Enterprise Value
Monthly Web Traffic		2.34K
Web Traffic Growth		-0.52
Valuation
Raised Capital		40M

Metric
Revenue	2.91M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-558K
EBITDA	-86.50M
Operating Income	-102.80M
Net Income	-94.82M
EPS	-1.30
Diluted EPS	-1.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.19
Operating Profit Margin	-35.31
EBITDA Margin	-29.71
Net Profit Margin	-32.06
Return on Equity	-0.45
Return on Assets	-0.35
Return on Capital Employed	-0.42

COM:SINGULARGENOMICS

Singular Genomics

Last Close

21.40

22/11 21:00

Market Cap

19.05M

Beta: -

Volume Today

10.54K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.45
P/B Ratio	0.20
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	291.31
EV Multiple	0.36

Metric
Days Sales Outstanding	468.52
Days Payables Outstanding	326.35
Days Inventory Outstanding	1.43K
Operating Cycle	1.63K
Cash Conversion Cycle	1.35K
Asset Turnover	0.01

Metric
Operating Cash Flow	-73.65M
Free Cash Flow	-74.62M
Cash Flow to Debt	-0.98
Operating Cash Flow/Sales	-25.30
Free Cash Flow Yield	-1.91

Metric
Cash & Equivalents	16.23M
Accounts Receivable	348K
Inventory	13.57M
Goodwill
Debt to Capitalization	0.32
Debt to Assets	0.27
Current Ratio	13.64
Quick Ratio	9.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	4.55
R&D to Revenue	18.05
SG&A to Revenue	9.08